Jeffrey Farrow - ZS Pharma Insider

ZS Pharma Inc -- USA Stock  

 89.98  0.02  0.02%

CFO and Principal Accounting Officer

Mr. Jeffrey S. Farrow is Chief Financial Officer Principal Financial and Accounting Officer of ZS Pharma Inc. Mr. Farrow previously served as the Chief Financial Officer of Hyperion Therapeutics Inc. a commercial pharmaceutical company from July 2010 until May 2015. In addition Mr. Farrow served as Hyperions Secretary from May 2011 to August 2013 and Vice President Finance from February 2010 to June 2010. From May 2008 to December 2009 Mr. Farrow was Vice President Finance at Evotec AG a drug discovery and development company where Mr. Farrow was responsible for Evotecs corporate treasury function and compliance with the Sarbanes Oxley Act as well as overseeing the finance and general administrative functions of the companys Renovis subsidiary. From January 2004 to May 2008 Mr. Farrow held various positions with the most recent being Vice President Finance and Chief Accounting Officer at Renovis Inc. a drug discovery and development company which was acquired by Evotec AG in May 2008. Previously Mr. Farrow held various positions over his seven years in the audit practice of KPMG LLP and was most recently a Senior Manager
Age: 52  CFO Since 2015      
650-458-4100  http://www.zspharma.com
Farrow holds a B.A. in Business Administration with a concentration in Corporationrationrationrate Finance from California State University at Fullerton.

Management Efficiency

The company has return on total asset (ROA) of (0.99) % which means that it has lost $0.99 on every $100 spent on asset. This is way below average.
The company currently holds 10.39 M in liabilities with Debt to Equity (D/E) ratio of 0.05 which may suggest the company is not taking enough advantage from borrowing. ZS Pharma Inc has Current Ratio of 10.05 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

ZS Pharma, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of nonabsorbed drugs to treat renal, cardiovascular, liver, and metabolic diseases. ZS Pharma Inc (ZSPH) is traded on NASDAQ General Markets in USA. It is located in TEXAS, U.S.A and employs 184 people. ZS Pharma is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add ZS Pharma Inc to your portfolio

Top Management

ZS Pharma Inc Leadership Team
Jeffrey Farrow, CFO
D Keyser, Director
Srinivas Akkaraju, Director, Ph.D
John Whiting, Director, MBA
Adam Tomasi, Executive, MBA
Robert Alexander, CEO, Ph.D
Marc Ostro, Director, Ph.D
Martin Babler, Director
Guy Nohra, Director, MBA
Alvaro Guillem, Founder, Ph.D
Jeffrey Keyser, COO
Cynthia Smith, Executive, MBA
Mark Asbury, President
Henrik Rasmussen, Executive, Ph.D
Kimberly Popovits, Director

Stock Performance

ZS Pharma Performance Indicators